For years, the default definitive treatment for patients with early-stage I non–small cell lung cancer (NSCLC) has been surgical resection, typically minimally invasive lobectomy with systematic lymph ...
You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical ...
Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer in general, and non-small cell lung cancer (NSCLC) in particular, is often asymptomatic in the early stages of the disease.
In patients with locally advanced non–small cell lung cancer (NSCLC), combining PET with invasive staging methods led to “relevant changes” of target volumes in 10% of cases, researchers reported.
The American College of Chest Physicians (CHEST) recently released a new clinical guideline on the management of patients with early-stage non-small cell lung cancer (NSCLC). Published in the journal ...
Adherence to quality metrics in early-stage NSCLC improves outcomes, but disparities exist among certain demographics, highlighting the need for equitable healthcare practices. Cemiplimab plus ...
Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is ...
CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results